Format

Send to

Choose Destination
Semin Oncol. 2007 Apr;34(2 Suppl 1):S37-40.

Adjuvant therapy for stage II and III colorectal cancer.

Author information

1
Groupe Coopérateur Multidisciplinaire en Oncologie, Hôpital Saint-Antoine, Service de Médecine Interne-Oncologie, 184 rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12, France. aimery.de-gramont@sat.ap-hop-paris.fr

Abstract

Considerable progress has been made in improving disease-free survival in stage III colon cancer with the use of adjuvant chemotherapy. In recent years, it has been shown that infusional 5-fluorouracil regimens maintain the efficacy and reduce toxicity associated with bolus 5-fluorouracil, that improved tolerability can be achieved with use of the oral fluoropyrimidine capecitabine, and that improved efficacy can be achieved by combining 5-fluorouracil/leucovorin with other cytotoxic agents (eg, oxaliplatin and irinotecan). Studies are ongoing to identify optimal adjuvant regimens in stage II or III disease and to identify the potential benefits of adding bevacizumab or cetuximab to adjuvant therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center